Yoland C. Antill

Yoland C. Antill

orcid

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 June 2021 in Journal for ImmunoTherapy of Cancer
Verified
Journal Article
Open access
PDF file
YAYoland C. Antill
Yoland C. Antill
PKPeey-Sei Kok
Peey-Sei Kok
KRKristy Robledo
Kristy Robledo
SYSonia Yip
Sonia Yip
MCMichelle Cummins
Michelle Cummins
LMLinda Mileshkin
Linda Mileshkin
Background In this study, we assessed the activity of durvalumab, an antibody to programmed death ligand-1, in two cohorts of women with advanced endometrial cancers (AEC)—mismatch repair proficient (pMMR) and mismatch repair deficient (dMMR). Methods A multicenter phase two study was performed in women with AEC with pMMR tumor progressing after one to three lines of chemotherapy and women with AEC with dMMR tumor progressing after zero to three lines of chemotherapy. Mismatch repair status was based on immunohistochemistry expression. All women received durvalumab 1500 mg given every 4 weeks until progression or unacceptable toxicity. The primary endpoint was objective tumor response by RECIST V.1.1 modified for immune-based therapeutics. Results Seventy-one women were recruited: 35 dMMR and 36 pMMR. Median follow-up was 19 vs 21 months in dMMR versus pMMR, respectively. Median age was 67 years. Histology in dMMR versus pMMR included endometrioid (94% vs 57%) and serous (0% vs 31%) and was high grade in 26% vs 74%. The objective tumor response rate (OTRR) in the dMMR cohort was 47% (17/36, 95% CI 32 to 63), including 6 complete responses and 11 partial responses (PRs)) vs 3% in the pMMR cohort (1/35, 95% CI 1 to 15, PR). In the dMMR cohort, durvalumab was the first-line therapy in 58% (OTRR 57%) and the second-line therapy in 39% (OTRR 38%). Median progression-free survival was 8.3 months in the dMMR cohort vs 1.8 months in the pMMR cohort. The 12-month overall survival (OS) rate was 71% in dMMR vs 51% in pMMR, with median OS not reached for dMMR vs 12 months for pMMR. Immune-related adverse events occurred in 14 women, mostly grades 1–2. Conclusion Durvalumab monotherapy showed promising activity and acceptable safety in AEC with dMMR regardless of prior lines of chemotherapy, but activity was limited in AEC with pMMR. Trial registration numbers ANZGOG1601, ACTRN12617000106336, and NCT03015129.

30 August 2021 in Psycho-Oncology
Verified
Journal Article
Closed access
PDF file
SKSeon‐Young Kim
Seon‐Young Kim
DKDavid Kissane
David Kissane
GRGary Richardson
Gary Richardson
JSJenny Senior
Jenny Senior
JMJoanna Morgan
Joanna Morgan
IBIrene Bobevski
Irene Bobevski

1 January 2019 in Journal of Gynecologic Oncology
Verified
Journal Article
Open access
PDF file
PKPeey-Sei Kok
Peey-Sei Kok
PBPhilip Beale
Philip Beale
RORachel Louise O'Connell
Rachel Louise O'Connell
PGPeter Grant
Peter Grant
TBTony Bonaventura
Tony Bonaventura
OIon behalf of the PARAGON Investigators
on behalf of the PARAGON Investigators
Kok PS, et al. J Gynecol Oncol. 2018 Aug;30:e86. https://doi.org/10.3802/jgo.2019.30.e86

20 May 2020 in Familial Cancer
Verified
Journal Article
Closed access
PDF file
TYT. Yanes
T. Yanes
RKRajneesh Kaur
Rajneesh Kaur
BMB. Meiser
B. Meiser
MSM. Scheepers-Joynt
M. Scheepers-Joynt
SMS. McInerny
S. McInerny
MYMary-Anne Young
Mary-Anne Young

18 November 2022 in ESMO Open
Verified
Journal Article
Open access
PKP.-S. Kok
P.-S. Kok
YAYoland C. Antill
Yoland C. Antill
CSClare L Scott
Clare L Scott
CLC.K. Lee
C.K. Lee
Immune checkpoint inhibitor (ICI) therapy is an emerging option for advanced endometrial cancer (EC). Mismatch repair (MMR) status is widely regarded as a biomarker predictive of response to ICIs. The predictive value of MMR based on small, single-arm trials, however, is conflicting. In this meta-analysis, we aimed to assess the activity of single-agent ICI in advanced EC, and compared the magnitude of treatment benefit in MMR deficient (dMMR) and MMR proficient (pMMR) EC. We carried out an electronic search to identify prospective trials of single-agent ICI in advanced EC. Data on objective response rate (ORR) and progression-free survival (PFS) were extracted and pooled. ORR was estimated using the inverse variance method and subgroup difference by MMR status was examined. PFS difference according to MMR status was summarized using the Kaplan–Meier approach. From eight trials with 492 women, the pooled ORR was 19% [95% confidence interval (CI) 16% to 22%]. ORR was significantly greater in dMMR (n = 281) than pMMR EC (n = 211) (dMMR: 46%, pMMR: 8%; risk ratio 5.74, 95% CI 3.58-9.21; interaction P < 0.001). Complete response was 11% and 0.05% and median PFS was 8.3 and 2.1 months in dMMR and pMMR EC, respectively (hazard ratio PFS 0.58, 95% CI 0.38-0.89; P = 0.01). The 12-month PFS rates were 42.0% and 20.7%, respectively. Single-agent ICI is associated with a 5.74 times greater objective response and 42% reduction in risk of disease progression or death in dMMR compared with pMMR EC. MMR status should be determined prospectively and be used as a stratification factor in future trials of advanced EC. Further translational analysis is urgently required to identify the cause of dMMR and allow subclassification of EC into different dMMR molecular subtypes.

1 January 2025 in Journal of Gynecologic Oncology
Verified
Journal Article
Open access
PDF file
KHKenichi Harano
Kenichi Harano
RFRoldano Fossati
Roldano Fossati
BPBeatriz Pardo
Beatriz Pardo
FGFrancesca Galli
Francesca Galli
EHEmma Hudson
Emma Hudson
NCNicoletta Colombo
Nicoletta Colombo
Harano K, et al. J Gynecol Oncol. 2025 Apr;36:e117. https://doi.org/10.3802/jgo.2025.36.e117